|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Fermbox Bio teams up with Dyadic for bio-alternatives & alternative protein
|
|
Monday, 05 June, 2023, 15 : 00 PM [IST]
|
|
Our Bureau, Bengaluru
|
Fermbox Bio, a synthetic biology company that uses microbial precision fermentation for the sustainable and commercially viable production of bio-alternatives, announced its collaboration agreement with Dyadic International Inc.
This marks Dyadic’s first collaboration with an Indian company for non-pharmaceutical applications on the Dapibus platform and will bring together Fermbox’s extensive product development and scale-up process engineering capabilities and Dyadic’s proprietary filamentous fungal-based microbial protein production platform to design, develop, and commercialise innovative animal-free alternative proteins and biomaterials.
“Our joint expertise across expression systems and execution capabilities from lab to large-scale manufacturing, uniquely positions us for success. We have a long-standing relationship with Dyadic leadership, and we believe that this co-development agreement can potentially accelerate the timelines for both companies to bring new and commercially viable bio-alternates to the market sooner,” said Subramani Ramachandrappa, founder, Fermbox.
Having operations both in the US and in India, Fermbox is uniquely positioned to collaborate globally and use its advantage of access to Indian scientific talent and manufacturing capabilities locally. The partnership will allow Fermbox to leverage India's expertise in gene expression and enzymatic pathway engineering to build highly productive microbial strains to develop a number of bioproducts. This capability, coupled with India’s strengths in low-cost manufacturing at industrial scale can propel the alternative protein sector, making India a viable supplier to the global industry. This collaboration is a milestone in the synthetic biology industry that has the potential to influence and inspire others to follow similar models to increase success rates for product development and viable commercialisation.
Joe Hazelton, chief business officer, Dyadic, stated, “Fermbox has extensive expertise in bio-alternatives development and microbial precision fermentation which we expect will accelerate our ability to exploit the Dapibus platform and expand Dyadic’s product offerings for non-pharmaceutical alternative proteins applications, such as food, nutrition, wellness, and other bioproducts. We believe that this collaboration will further leverage our proprietary Dapibus platform toward developing and commercialising multiple end-market animal-free protein products.”
Nicole Rocque, senior innovation specialist, The Good Food Institute (GFI) India, said, “A co-development partnership of this kind highlights the emerging role India can play in the global SynBio industry, not just as a scale-up and manufacturing location but also by harnessing India’s research capabilities to develop future-proof technologies.
|
|
|
|
|
|
|
|
|
|